

Supplementary Figure 1. Patient flow diagram. HbA1c, glycated hemoglobin; LDL-C, low-density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; BMI, body mass index.



Supplementary Figure 2. Temporal trends in pre-admission OAC use at recurrent ischemic stroke, stratified by atrial fibrillation ascertainment status, Korean Stroke Registry 2018–2023. Annual proportions of patients receiving pre-admission OAC therapy are shown for two distinct cohorts at recurrent stroke admission: (1) patients with known (pre-existing) AF documented before the current admission (orange; n=4,441), for whom pre-admission OAC non-use reflects a secondary prevention gap; and (2) patients whose atrial fibrillation was first identified during the current recurrent stroke hospitalization (teal; n=1,575), for whom pre-admission OAC non-use reflects undiagnosed atrial fibrillation rather than prevention failure. Proportions are unadjusted. Shaded bands represent 95% confidence intervals (Wilson). OAC, oral anticoagulant; AF, atrial fibrillation.